Clearmind Medicine Soars 32.89% on Clinical Trial Approval

Clearmind Medicine's stock surged by 32.89% in pre-market trading on July 4, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Clearmind Medicine has made substantial progress in its clinical trials, particularly with the approval of its Phase 1/2a clinical trial by the Institutional Review Board (IRB). This multinational, multi-center study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, a proprietary MEAI-based oral drug candidate. The trial aims to address alcohol use disorder, a condition that affects millions of people worldwide.

The approval from Tel Aviv Sourasky Medical Center (TASMC) is a significant milestone for Clearmind Medicine, as it validates the company's approach to developing novel psychedelic drugs for treating alcohol use disorder. This development has generated considerable interest in the medical community and among investors, who see the potential for groundbreaking treatments in the field of mental health.

The company's focus on innovative treatments and its commitment to rigorous clinical trials have positioned it as a leader in the psychedelic medicine sector. With the IRB approval, Clearmind Medicine is poised to advance its clinical trials and bring its groundbreaking treatments closer to market, potentially revolutionizing the way alcohol use disorder is managed.